These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10637239)

  • 1. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.
    Stark A; Hulka BS; Joens S; Novotny D; Thor AD; Wold LE; Schell MJ; Melton LJ; Liu ET; Conway K
    J Clin Oncol; 2000 Jan; 18(2):267-74. PubMed ID: 10637239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations in benign breast tissue.
    Millikan R; Hulka B; Thor A; Zhang Y; Edgerton S; Zhang X; Pei H; He M; Wold L; Melton LJ
    J Clin Oncol; 1995 Sep; 13(9):2293-300. PubMed ID: 7666086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
    Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
    Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
    Huang WY; Newman B; Millikan RC; Conway K; Hulka BS; Schell MJ; Liu ET
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):65-71. PubMed ID: 10667465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
    Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
    Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
    Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
    Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2/neu gene amplification and protein expression in primary male breast cancer.
    Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
    Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.
    Moore JG; To V; Patel SJ; Sneige N
    Diagn Cytopathol; 2000 Nov; 23(5):299-302. PubMed ID: 11074621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
    Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
    Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
    Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
    Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
    Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.